What they were paid
Inhibikase Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $31,400 | — | $0 | — | $31,400 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Inhibikase Therapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001193125-26-197177, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Inhibikase Therapeutics pays directors a $60,000 cash retainer and $150,000 in equity.
The rest of the Inhibikase Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Dr. David Canner | Independent Director | $448,011 |
| Mark Iwicki | Director | $0 |
| Mr. Amit Munshi | Independent Director | $542,394 |
| Mr. Arvind Kush | Independent Director | $537,344 |
| Mr. Dennis Berman | Independent Director | $306,426 |
| Mr. Roberto Bellini | Independent Director | $572,560 |
| Mr. Vincent Aurentz | Independent Director | $500,531 |
The full Inhibikase Therapeutics compensation record
free company briefThis page is one director within Inhibikase Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat